Corporate Profile

Nanosphere, Inc. is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics.

Our platform, the Verigene® System, enables clinicians to rapidly identify and treat many of the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. The Verigene System uses Nanosphere’s proprietary gold nanoparticle chemistry to offer simple-to-use, highly accurate multiplex molecular diagno... More >>

Stock Quote
NSPH (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.74
Change (%)0.00 (1.37%)
Volume1,308,815
Data as of 10/21/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: 03NA000000NSPH
PresentationsMore >>
DateTitle
08/13/14
Download Documentation Canaccord Genuity Growth Conference
Recent NewsMore >>
10/21/14 - 4:01 p.m.
Nanosphere Announces Commencement of Public Offering of Common Stock; Preliminary Third Quarter 2014 Top Line Results
10/13/14 - 8:00 a.m.
FDA Clears Additional Viral Targets on Verigene Enteric Pathogens Test
09/08/14 - 8:01 a.m.
New Outcomes Data Presented at ICAAC 2014 Further Validates Clinical and Economic Utility of Nanosphere's Verigene Blood Culture Test
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Print Page Print Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet